Conferences related to Cancer drugs

Back to Top

2020 42nd Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)

The conference program will consist of plenary lectures, symposia, workshops and invitedsessions of the latest significant findings and developments in all the major fields of biomedical engineering.Submitted papers will be peer reviewed. Accepted high quality papers will be presented in oral and postersessions, will appear in the Conference Proceedings and will be indexed in PubMed/MEDLINE


2020 59th IEEE Conference on Decision and Control (CDC)

The CDC is the premier conference dedicated to the advancement of the theory and practice of systems and control. The CDC annually brings together an international community of researchers and practitioners in the field of automatic control to discuss new research results, perspectives on future developments, and innovative applications relevant to decision making, automatic control, and related areas.


2020 IEEE 17th International Symposium on Biomedical Imaging (ISBI 2020)

The IEEE International Symposium on Biomedical Imaging (ISBI) is the premier forum for the presentation of technological advances in theoretical and applied biomedical imaging. ISBI 2020 will be the 17th meeting in this series. The previous meetings have played a leading role in facilitating interaction between researchers in medical and biological imaging. The 2020 meeting will continue this tradition of fostering cross-fertilization among different imaging communities and contributing to an integrative approach to biomedical imaging across all scales of observation.

  • 2019 IEEE 16th International Symposium on Biomedical Imaging (ISBI)

    The IEEE International Symposium on Biomedical Imaging (ISBI) is the premier forum for the presentation of technological advances in theoretical and applied biomedical imaging.ISBI 2019 will be the 16th meeting in this series. The previous meetings have played a leading role in facilitating interaction between researchers in medical and biological imaging. The 2019 meeting will continue this tradition of fostering cross fertilization among different imaging communities and contributing to an integrative approach to biomedical imaging across all scales of observation.

  • 2018 IEEE 15th International Symposium on Biomedical Imaging (ISBI 2018)

    The IEEE International Symposium on Biomedical Imaging (ISBI) is the premier forum for the presentation of technological advances in theoretical and applied biomedical imaging. ISBI 2018 will be the 15th meeting in this series. The previous meetings have played a leading role in facilitating interaction between researchers in medical and biological imaging. The 2018 meeting will continue this tradition of fostering crossfertilization among different imaging communities and contributing to an integrative approach to biomedical imaging across all scales of observation.

  • 2017 IEEE 14th International Symposium on Biomedical Imaging (ISBI 2017)

    The IEEE International Symposium on Biomedical Imaging (ISBI) is the premier forum for the presentation of technological advances in theoretical and applied biomedical imaging. ISBI 2017 will be the 14th meeting in this series. The previous meetings have played a leading role in facilitating interaction between researchers in medical and biological imaging. The 2017 meeting will continue this tradition of fostering crossfertilization among different imaging communities and contributing to an integrative approach to biomedical imaging across all scales of observation.

  • 2016 IEEE 13th International Symposium on Biomedical Imaging (ISBI 2016)

    The IEEE International Symposium on Biomedical Imaging (ISBI) is the premier forumfor the presentation of technological advances in theoretical and applied biomedical imaging. ISBI 2016 willbe the thirteenth meeting in this series. The previous meetings have played a leading role in facilitatinginteraction between researchers in medical and biological imaging. The 2016 meeting will continue thistradition of fostering crossfertilization among different imaging communities and contributing to an integrativeapproach to biomedical imaging across all scales of observation.

  • 2015 IEEE 12th International Symposium on Biomedical Imaging (ISBI 2015)

    The IEEE International Symposium on Biomedical Imaging (ISBI) is the premier forum for the presentation of technological advances in theoretical and applied biomedical imaging. ISBI 2015 will be the 12th meeting in this series. The previous meetings have played a leading role in facilitating interaction between researchers in medical and biological imaging. The 2014 meeting will continue this tradition of fostering crossfertilization among different imaging communities and contributing to an integrative approach to biomedical imaging across all scales of observation.

  • 2014 IEEE 11th International Symposium on Biomedical Imaging (ISBI 2014)

    The IEEE International Symposium on Biomedical Imaging (ISBI) is the premier forum for the presentation of technological advances in theoretical and applied biomedical imaging. ISBI 2014 will be the eleventh meeting in this series. The previous meetings have played a leading role in facilitating interaction between researchers in medical and biological imaging. The 2014 meeting will continue this tradition of fostering crossfertilization among different imaging communities and contributing to an integrative approach to biomedical imaging across all scales of observation.

  • 2013 IEEE 10th International Symposium on Biomedical Imaging (ISBI 2013)

    To serve the biological, biomedical, bioengineering, bioimaging and other technical communities through a quality program of presentations and papers on the foundation, application, development, and use of biomedical imaging.

  • 2012 IEEE 9th International Symposium on Biomedical Imaging (ISBI 2012)

    To serve the biological, biomedical, bioengineering, bioimaging, and other technical communities through a quality program of presentations and papers on the foundation, application, development, and use of biomedical imaging.

  • 2011 IEEE 8th International Symposium on Biomedical Imaging (ISBI 2011)

    To serve the biological, biomedical, bioengineering, bioimaging, and other technical communities through a quality program of presentations and papers on the foundation, application, development, and use of biomedical imaging.

  • 2010 IEEE 7th International Symposium on Biomedical Imaging (ISBI 2010)

    To serve the biological, biomedical, bioengineering, bioimaging, and other technical communities through a quality program of presentations and papers on the foundation, application, development, and use of biomedical imaging.

  • 2009 IEEE 6th International Symposium on Biomedical Imaging (ISBI 2009)

    Algorithmic, mathematical and computational aspects of biomedical imaging, from nano- to macroscale. Topics of interest include image formation and reconstruction, computational and statistical image processing and analysis, dynamic imaging, visualization, image quality assessment, and physical, biological and statistical modeling. Molecular, cellular, anatomical and functional imaging modalities and applications.

  • 2008 IEEE 5th International Symposium on Biomedical Imaging (ISBI 2008)

    Algorithmic, mathematical and computational aspects of biomedical imaging, from nano- to macroscale. Topics of interest include image formation and reconstruction, computational and statistical image processing and analysis, dynamic imaging, visualization, image quality assessment, and physical, biological and statistical modeling. Molecular, cellular, anatomical and functional imaging modalities and applications.

  • 2007 IEEE 4th International Symposium on Biomedical Imaging: Macro to Nano (ISBI 2007)

  • 2006 IEEE 3rd International Symposium on Biomedical Imaging: Macro to Nano (ISBI 2006)

  • 2004 2nd IEEE International Symposium on Biomedical Imaging: Macro to Nano (ISBI 2004)

  • 2002 1st IEEE International Symposium on Biomedical Imaging: Macro to Nano (ISBI 2002)


2020 IEEE International Conference on Plasma Science (ICOPS)

IEEE International Conference on Plasma Science (ICOPS) is an annual conference coordinated by the Plasma Science and Application Committee (PSAC) of the IEEE Nuclear & Plasma Sciences Society.


2020 IEEE International Magnetic Conference (INTERMAG)

INTERMAG is the premier conference on all aspects of applied magnetism and provides a range of oral and poster presentations, invited talks and symposia, a tutorial session, and exhibits reviewing the latest developments in magnetism.


More Conferences

Periodicals related to Cancer drugs

Back to Top

Applied Superconductivity, IEEE Transactions on

Contains articles on the applications and other relevant technology. Electronic applications include analog and digital circuits employing thin films and active devices such as Josephson junctions. Power applications include magnet design as well asmotors, generators, and power transmission


Automatic Control, IEEE Transactions on

The theory, design and application of Control Systems. It shall encompass components, and the integration of these components, as are necessary for the construction of such systems. The word `systems' as used herein shall be interpreted to include physical, biological, organizational and other entities and combinations thereof, which can be represented through a mathematical symbolism. The Field of Interest: shall ...


Automation Science and Engineering, IEEE Transactions on

The IEEE Transactions on Automation Sciences and Engineering (T-ASE) publishes fundamental papers on Automation, emphasizing scientific results that advance efficiency, quality, productivity, and reliability. T-ASE encourages interdisciplinary approaches from computer science, control systems, electrical engineering, mathematics, mechanical engineering, operations research, and other fields. We welcome results relevant to industries such as agriculture, biotechnology, healthcare, home automation, maintenance, manufacturing, pharmaceuticals, retail, ...


Biomedical Circuits and Systems, IEEE Transactions on

The Transactions on Biomedical Circuits and Systems addresses areas at the crossroads of Circuits and Systems and Life Sciences. The main emphasis is on microelectronic issues in a wide range of applications found in life sciences, physical sciences and engineering. The primary goal of the journal is to bridge the unique scientific and technical activities of the Circuits and Systems ...


Biomedical Engineering, IEEE Transactions on

Broad coverage of concepts and methods of the physical and engineering sciences applied in biology and medicine, ranging from formalized mathematical theory through experimental science and technological development to practical clinical applications.


More Periodicals

Most published Xplore authors for Cancer drugs

Back to Top

Xplore Articles related to Cancer drugs

Back to Top

Towards automated bioimage analysis: from features to semantics

3rd IEEE International Symposium on Biomedical Imaging: Nano to Macro, 2006., 2006

Recent advances in bio-molecular imaging have afforded biologists a more thorough understanding of cellular functions in complex tissue structures. For example, high resolution fluorescence images of the retina reveal details about tissue restructuring during detachment experiments. Time sequence imagery of microtubules provides insight into subcellular dynamics in response to cancer treatment drugs. However, technological progress is accompanied by a rapid ...


Classification of Cancerous Profiles Using Machine Learning

2017 International Conference on Machine Learning and Data Science (MLDS), 2017

There are a variety of options available for cancer treatment. The type of treatment recommended for an individual is influenced by various factors such as cancer-type, the severity of a cancer (stage) and most important the genetic heterogeneity. In such a complex environment, the targeted drug treatments are likely to be irresponsive or respond differently. To study anti-cancer drug response ...


Optofluidic time-stretch microscopy for precision medicine

2018 Conference on Lasers and Electro-Optics (CLEO), 2018

We present the principle of optofluidic time-stretch microscopy and its application to precision medicine. Its ability to perform multiparametric image-based profiling of numerous single cells enables biomedical data mining with the help of machine learning.


Chemoradiotherapy of ME-180 Tumors with an Intratumoral Cisplatin/Calcium Phosphate Drug Delivery System

Proceedings of the IEEE 32nd Annual Northeast Bioengineering Conference, 2006

Drug delivery systems are able to concentrate cancer drugs in a localized region, thereby increasing drug effectiveness. Side effects are decreased due to reduced systemic drug exposure. This in vivo study investigates the use of a calcium phosphate (CaP) crystal drug delivery system to deliver cisplatin (CDDP) into murine ME-180 tumors. Forty-two athymic Ner-nu/nu mice were put into six groups: ...


Nanosecond pulsed electric fields adjuvant chemotherapy for breast cancer: An in vitro study

2013 19th IEEE Pulsed Power Conference (PPC), 2013

Chemotherapeutic resistance and adverse effects induced by chemotherapy are major problems of chemotherapy in breast cancer treatment. Lots of efforts have been put into discovering of better therapy for breast cancer. Nanosecond pulsed electric fields has been reported as an efficient drug-free approach to induce cell apoptosis. In the study, we used nanosecond pulsed electric fields adjuvant to gemcitabine, an ...


More Xplore Articles

Educational Resources on Cancer drugs

Back to Top

IEEE-USA E-Books

  • Towards automated bioimage analysis: from features to semantics

    Recent advances in bio-molecular imaging have afforded biologists a more thorough understanding of cellular functions in complex tissue structures. For example, high resolution fluorescence images of the retina reveal details about tissue restructuring during detachment experiments. Time sequence imagery of microtubules provides insight into subcellular dynamics in response to cancer treatment drugs. However, technological progress is accompanied by a rapid proliferation of image data. Traditional analysis methods, namely manual measurements and qualitative assessments, become time consuming and are often nonreproducible. Computer vision tools can efficiently analyze these vast amounts of data with promising results. This paper provides an overview of several challenges faced in bioimage processing and our recent progress in addressing these issues

  • Classification of Cancerous Profiles Using Machine Learning

    There are a variety of options available for cancer treatment. The type of treatment recommended for an individual is influenced by various factors such as cancer-type, the severity of a cancer (stage) and most important the genetic heterogeneity. In such a complex environment, the targeted drug treatments are likely to be irresponsive or respond differently. To study anti-cancer drug response we need to understand cancerous profiles. These cancerous profiles carry information which can reveal the underlying factors responsible for cancer growth. Hence, there is need to analyze cancer data for predicting optimal treatment options. Analysis of such profiles can help to predict and discover potential drug targets and drugs. In this paper the main aim is to provide machine learning based classification technique for cancerous profiles.

  • Optofluidic time-stretch microscopy for precision medicine

    We present the principle of optofluidic time-stretch microscopy and its application to precision medicine. Its ability to perform multiparametric image-based profiling of numerous single cells enables biomedical data mining with the help of machine learning.

  • Chemoradiotherapy of ME-180 Tumors with an Intratumoral Cisplatin/Calcium Phosphate Drug Delivery System

    Drug delivery systems are able to concentrate cancer drugs in a localized region, thereby increasing drug effectiveness. Side effects are decreased due to reduced systemic drug exposure. This in vivo study investigates the use of a calcium phosphate (CaP) crystal drug delivery system to deliver cisplatin (CDDP) into murine ME-180 tumors. Forty-two athymic Ner-nu/nu mice were put into six groups: untreated control, systemic CDDP, and the CDDP/CaP drug delivery system with, and without, an 8Gy radiation dose. The CDDP/CaP was injected via a 25 gauge needle directly into the intradermal tumor. Tumors were measured daily as well as mouse weight. Data was recorded for 26 days. At the end of 26<sup>th</sup>day mice were sacrificed and the tumors removed for further studies. Analysis showed the CDDP/CaP drug delivery system was significantly more effective against tumor growth when used alone or with radiation as compared to systemically delivered CDDP alone or with radiaton. Tumors treated with the CDDP/CaP drug delivery system were smaller in volume, or had completed regressed, when compared to the rest of the groups. Also, the CDDP/CaP groups exhibited less weight loss, an indication of reduced systemic toxicity.

  • Nanosecond pulsed electric fields adjuvant chemotherapy for breast cancer: An in vitro study

    Chemotherapeutic resistance and adverse effects induced by chemotherapy are major problems of chemotherapy in breast cancer treatment. Lots of efforts have been put into discovering of better therapy for breast cancer. Nanosecond pulsed electric fields has been reported as an efficient drug-free approach to induce cell apoptosis. In the study, we used nanosecond pulsed electric fields adjuvant to gemcitabine, an anti-cancer drug widely used in clinics, as a novel combined therapy to increase the effects of treatment. Two cell lines were tested in the study. Human breast cancer cell line MCF-7 and MDA-MB-231. Cells were exposed to nsPEFs prior to low concentration of gemcitabine. It was observed that the combined treatment of nsPEF and gemcitabine significantly inhibited growth of both cell lines. The inhibition fraction could achieve 2 times greater than that induced by 0.38uM gemcitabine alone. The prior treatment of nsPEFs could sensitize the cells and thus enhance the effects of chemotherapeutic drugs. Similarly, apoptosis fraction increased significantly by adding nsPEF to the drug treatment. The proportion of early apoptosis could reach over 50% after pulsed plus 0.1ug/mL gemcitabine, which is 2-fold increase compared with gemcitabine alone treated cells. Morphological changes were observed by H&amp;E staining. The results indicate that nsPEF can effectively enhance the inhibition of low concentration gemcitabine in breast cancer.

  • High-throughput screening of chemopreventive compounds targeting Nrf2

    Cancer is an aging-related disease promoted by accumulation of cellular damage under stressful environment. Many natural products, known as chemopreventive compounds, can lower the risk of cancer by enhancing cellular capacity of handling stress. Studies of molecular targets of these compounds have led to the identification of a novel transcription factor Nrf2 that is a master regulator of a major cellular antioxidant response. The critical role of Nrf2 in chemoprevention has been recently established. Using small molecule Nrf2 activators for chemoprevention represents an innovative strategy for fighting against cancer. In this study, we demonstrated the feasibility of high- throughput screening of Nrf2 activators using a luciferase reporter gene assay as a primary screen. Hit confirmation was performed in a secondary screen based on immunodetection of the Nrf2 protein. For bioefficacy study, compound- induced upregulation of hemeoxygenase I (HO-1) and NAD(P)H-quinone oxidoreductase (NQO1), two well studied Nrf2 target genes involved in the cellular antioxidant response, was detected using real time RT-PCR analysis. NQOl enzymatic activity and intracellular glutathione level were assessed as the downstream effects of Nrf2 activation by these compounds. Although several Nrf2 activators have been identified using these approaches, it is time consuming and labor intensive. Development of sensitive devices for rapid, reliable, and high-throughput identification of Nrf2 activators will greatly speed up the identification of new drugs for chemoprevention.

  • Turning the Unknown into Known: Data Mining Is Increasingly Used to Prospect for Rare-Disease Biology and Treatments

    Taken as a whole, rare diseases are not very rare. Even though a rare disease by definition is one that affects fewer than 200,000 Americans or fewer than one in 2,000 Europeans at any time, when rare diseases are considered together, they affect some 350 million people worldwide, or about 5% of the population (Figure 1). What is even more alarming is that 7,800 of the approximately 8,000 known rare diseases have no treatments available. It's not that rare diseases are harder to treat than more widespread illnesses. Rather, compared to more common disorders, rare diseases simply do not draw the same level of attention from granting agencies, pharmaceutical companies, medical professionals, and researchers, so they languish in the shadows. That means patients and patients' families are often the ones scrambling to get information, poring through scientific journals for details about biology and chemistry, and scouring the Internet to find something that will fight the symptoms or the disease itself. This is about to change, according to rare- disease experts. And it's thanks to big data and new data-mining approaches that are poised to compile and analyze information from obscure and sometimes disparate resources in a much faster and more methodical manner. The objective is to help patients get correct diagnoses earlier and to reveal more treatment options.

  • Genetic function approximation in the molecular pharmacology of cancer

    The National Cancer Institute's Developmental Therapeutics Program screens more than 10,000 compounds per year for their ability to inhibit growth of 60 human cancer cell lines. Using a combination of cross-validated backpropagation neural networks and multivariate statistical methods, we found that a compound's mechanism of action could be predicted with considerable accuracy solely on the basis of its pattern of growth inhibitory activity against the 60 cell lines (Weinstein, et al. 1992, 1997). Over the last several years, the developments, in terms of different mathematical approaches, led to formulation of a general "information-intensive" strategy for drug discovery that integrates data on a compounds's molecular structure, pattern of growth inhibitory activity, and possible molecular targets in the cell. Here we summarize our recent investigations of a new approach to the regression problem, "genetic function approximation".

  • Fluorescence-enhanced optical imaging and tomography for cancer diagnostics

    The discovery and development of molecularly based drugs has been progressing at a rapid pace necessitating the development of diagnostic methods for identification of molecular targets for individual tailoring of therapy. The clinical standard of molecular imaging is currently nuclear imaging whether for planar scintigraphy imaging with gamma emitters or for tomographic imaging with gamma or positron emitters. The use of near-infrared excitable fluorescent agents conjugated to targeting moieties can also be used to provide a new, nonionizing form of molecular imaging. In this contribution, we summarize the advances in planar optical imaging as well as tomography using near-infrared fluorescent contrast agents and compare future prospects in light of the current state of nuclear imaging modalities.

  • The Clinical Utility of Circulationg Tumor Cells: Analysis of These Cells May Have the Potential to Assist with Screening and Diagnosing Cancer

    Circulating tumor cells (CTCs) do hold the potential to significantly assist with clinical decision making. However, for CTC analysis to achieve clinical uptake, there need to be standardized platforms and protocols for isolating and analyzing CTCs as well as more focused and relevant prognostic information, which will require several additional controlled clinical trials to determine the true benefit of CTC isolation and analysis. Such studies- several of which are currently underway, with many more planned in the near future-will likely yield actionable information so that clinicians can utilize CTC analysis as an additional piece of information with which to guide treatment determinations and help predict outcomes.



Standards related to Cancer drugs

Back to Top

No standards are currently tagged "Cancer drugs"


Jobs related to Cancer drugs

Back to Top